Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system

Clinical and Vaccine Immunology

Volumn 17, Issue 5, 2010, Pages 784-792

  Zichel, R ^a   Mimran, A ^a   Keren, A ^a   Barnea, A ^a   Steinberger Levy, I ^a   Marcus, D ^a   Turgeman, A ^a   Reuveny, S ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; PROTEIN DISULFIDE ISOMERASE; RECOMBINANT PROTEIN; TRIPLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BOTULISM; CARBOXY TERMINAL SEQUENCE; CELL FREE SYSTEM; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; HEAVY CHAIN; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PURIFICATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, BACTERIAL; ANTITOXINS; BACTERIAL VACCINES; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; BOTULISM; CELL-FREE SYSTEM; CHROMATOGRAPHY, AFFINITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION, SECONDARY; MICE; PROTEIN SUBUNITS; VACCINATION; VACCINES, SYNTHETIC;

EID: 77951985187     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00496-09     Document Type: Article

References (58)

1. Arimitsu, H., K. Inoue, Y. Sakaguchi, J. Lee, Y. Fujinaga, T. Watanabe, T. Ohyama, R. Hirst, and K. Oguma. 2003. Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia. Infect. Immun. 71:1599-1603.
2. Arnon, S. S., R. Schechter, T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, J. Hauer, M. Layton, S. Lillibridge, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russel, D. L. Swerdlow, and K. Tonat. 2001. Botulinum toxin as a biological weapon: medical and public health managment. JAMA 285:1059-1070.
3. Baldwin, M. R., W. H. Tepp, A. Przedpelski, C. L. Pier, M. Bradshaw, E. A. Johnson, and J. T. Barbieri. 2008. Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 76:1314-1318.
4. Binz, T., H. Kurazono, M. Wille, J. Frevert, K. Wernars, and H. Nieman. 1990. The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins. J. Biol. Chem. 265:9153-9158.
5. Boles, J., M. West, V. Montgomery, R. Tammariello, M. Pitt, P. Gibbs, L. Smith, and R. LeClaire. 2006. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (Hc)) immune response and protection in the rhesus monkey. Toxicon 47:877-884.
6. Byrne, M. P., and L. A. Smith. 2000. Development of vaccines for prevention of botulism. Biochimie 82:955-966.
7. Byrne, M. P., R.W. Titball, J. Holley, and L. A. Smith. 2000. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum type F from Pichia pastoris. Protein Expr. Purif. 18:327-337.
8. Calhoun, K. A., and J. R. Swartz. 2005. An economical method for cell-free protein synthesis using glucose and nucleoside monophosphates. Biotechnol. Prog. 21:1146-1153.
9. Clayton, M. A., M. J. Clayton, R. D. Brown, and J. L. Middlebrook. 1995. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun. 63:2738-2742.
10. DePalma, A. 2009. Making bioprocess scale-up more robust. Genet. Eng. Biotechnol. News 29:44-47.
11. Dux, M. P., R. Barent, J. Sinha, M. Gouthro, T. Swanson, A. Barthuli, M. Inan, J. T. Ross, L. A. Smith, T. J. Smith, R. Webb, B. Loveless, I. Henderson, and M. M. Meagher. 2006. Purification and scale-up of a recombinant heavy chain fragment C of botulinum neurotoxin serotype E in Pichia pastoris GS115. Protein Expr. Purif. 45:359-367.
12. Elbaz, Y., S. Steiner-Mordoch, T. Danieli, and S. Schuldiner. 2004. In vitro synthesis of fully functional EmrE, a multidrug transporter, and study of its oligomeric state. Proc. Natl. Acad. Sci. U. S. A. 101:1519-1524.
13. Fairweather, N. F., V. A. Lyness, and D. J. Maskell. 1987. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect. Immun. 55:2541-2545.
14. Fernholz, E., K. Zaiss, H. Besir, and W. Mutter. 2002. The expression of disulfide bonded protein in cell-free protein expression, p. 175-179. In A. S. Spirin (ed.), Cell-free translation systems. Springer, Berlin, Germany.
15. Fiock, M., M. A. Cardella, and N. F. Gearringer. 1963. Studies on immunity of Clostridium botulinum. IX. Immunologic response of man to purified pentavalent ABCDE botulinum toxoid. J. Immunol. 90:697-702.
16. Fox, J. D., K. M. Routzahn, M. H. Bucher, and D. S. Waugh. 2003. Maltodextrin-binding proteins from diverse bacteria and archaea are potent solubility enhancers. FEBS Lett. 537:53-57.
17. Frey, S., M. Haslbeck, O. Hainzl, and J. Buchner. 2008. Synthesis and characterization of a functional intact IgG in a prokaryotic cell-free expression system. Biol. Chem. 389:37-45.
18. Goerke, A. R., and J. R. Swartz. 2008. Development of cell-free protein synthesis platforms for disulfide bonded proteins. Biotechnol. Bioeng. 99:351-367.
19. Holley, J. L., M. Elmore, M. Mauchline, N. Minton, and R. W. Titball. 2000. Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine 19:288-297.
20. Jewett, M. C., and J. R. Swartz. 2004. Mimicking the Escherichia coli cytoplasmic environment activates long-lived and efficient cell-free protein synthesis. Biotechnol. Bioeng. 86:19-26.
21. Jiang, X., Y. Ookubo, I. Fujii, H. Nakano, and T. Yamane. 2002. Expression of Fab fragment of catalytic antibody 6D9 in an Escherichia coli in vitro coupled transcription/translation system. FEBS Lett. 514:290-294.
22. Kawarasaki, Y., T. Kawai, H. Nakano, and T. Yamane. 1995. A long-lived batch reaction system of cell-free protein synthesis. Anal. Biochem. 226:320-324.
23. Kigawa, T., T. Yabuki, Y. Yoshida, M. Tsutsui, Y. Ito, T. Shibata, and S. Yokoyama. 1999. Cell-free production and stable-isotope labeling of milligram quantities of proteins. FEBS Lett. 442:15-19. (Pubitemid 29065369)
24. Kim, D. M., E. Fernholz, and J. Swartz. 2003. cell-free expression of proteins containing multiple disulfide bonds, p. 125-131. In J. Swartz (ed.), cell-free protein expression. Springer-Verlag, Heidelberg, Germany.
25. Kim, R. G., and C. Y. Choi. 2001. Expression-independent consumption of substrates in cell-free expression system from Escherichia coli. J. Biotechnol. 84:27-32.
26. Klammt, C., S. Daniel, F. Lohr, B. Schneider, V. Dotsch, and F. Bernhard. 2006. Cell-free expression as an emerging technique for the large scale production of integral membrane protein. FEBS J. 273:4141-4153.
27. Kukreja, R., T. W. Chang, S. Cai, P. Lindo, S. Riding, Y. Zhou, E. Ravichandran, and B. R. Singh. 2009. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon 53:616-624.
28. Lacy, D. B., and R. C. Stevens. 1999. Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol. 291:1091-1104.
29. LaPenotiere, H. F., M. A. Clayton, and J. L. Middlebrook. 1995. Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Toxicon 33:1383-1386.
30. Li, L., and R. Singh. 1999. In vitro translation of type a Clostridium botulinum neurotoxin heavy chain and analysis of its binding to rat synaptosomes. J. Protein Chem. 18:89-95.
31. Madin, K., T. Sawasaki, T. Ogasawara, and Y. Endo. 2000. A highly efficient and robust cell-free protein synthesis system prepared from wheat embryos: plants apparently contain a suicide system directed at ribosomes. Proc. Natl. Acad. Sci. U. S. A. 97:559-564.
32. Makoff, A. J., M. D. Oxer, M. A. Romanos, N. F. Fairweather, and S. Ballantine. 1989. Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons. Nucleic Acids Res. 17:10191-10202.
33. Martemyanov, K. A., A. S. Spirin, and A. T. Gudkov. 1997. Direct expression of PCR products in a cell-free transcription/translation system: synthesis of antibacterial peptide cecropin. FEBS Lett. 414:268-270.
34. Merk, H., D. Meschkat, and W. Stiege. 2003. Expression-PCR: from gene pools to purified proteins within 1 day, p. 15-23. In J. Swartz (ed.), Cell-free protein expression. Springer-Verlag, Heidelberg, Germany.
35. Middlebrook, J. L. 1995. Protection strategies against botulinum toxin. Adv. Exp. Med. Biol. 383:93-98.
36. Nishihara, K., M. Kanemori, H. Yanagi, and T. Yura. 2000. Overexpression of trigger factor prevents aggregation of recombinant proteins in Escherichia coli. Appl. Environ. Microbiol. 66:884-889.
37. Park, N., S. H. Um, H. Funabashi, J. Xu, and D. Luo. 2009. A cell-free protein-producing gel. Nat. Mater. 8:432-437.
38. Ravichandran, E., F. H. Al-Saleem, D. M. Ancharski, M. D. Elias, A. K. Singh, M. Shamim, Y. Gong, and L. L. Simpson. 2007. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect. Immun. 75:3043-3054.
39. Romanos, M. A., A. J. Makoff, N. F. Fairweather, K. M. Beesley, D. E. Slater, F. B. Rayment, M. M. Payne, and J. J. Clare. 1991. Expression of tetanus toxin fragment C in yeast: gene synthesis is required to eliminate fortuitous polyadenylation sites in AT-rich DNA. Nucleic Acids Res. 19:1461-1467.
40. Sawasaki, T., T. Ogasawara, R. Morishita, and Y. Endo. 2002. A cell-free protein synthesis system for high-throughput proteomics. Proc. Natl. Acad. Sci. U. S. A. 99:14652-14657.
41. Smith, L. A. 1998. Development of recombinant vaccines for botulinum neurotoxin. Toxicon 36:1539-1548.
42. Smith, L. A., M. J. Jensen, V. A. Montgomery, D. R. Brown, S. A. Ahmed, and T. J. Smith. 2004. Roads from vaccines to therapies. Mov. Disord. 19:S48-S52.
43. Smith, L. A., and J. M. Rusnak. 2007. Botulinum neurotoxin vaccines: past, present, and future. Crit. Rev. Immunol. 27:303-318.
44. Smith, T. J., J. Lou, I. N. Geren, C. M. Forsyth, R. Tsai, S. L. LaPorte, W. H. Tepp, M. Bradshaw, E. A. Johnson, L. A. Smith, and J. D. Marks. 2005. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 73:5450-5457.
45. Spirin, A. S., V. I. Baranov, L. A. Ryabova, S. Y. Ovodov, and Y. B. Alakhov. 1988. A continuous cell-free translation system capable of producing polypeptides in high yield. Science 242:1162-1164.
46. Swartz, J. 2006. Developing cell-free biology for industrial applications. J. Ind. Microbiol. Biotechnol. 33:476-485.
47. Takahashi, T., S. G. Joshi, F. Al-Saleem, D. Ancharski, A. Singh, Z. Nasser, and L. L. Simpson. 2009. Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine 27:2616-2624.
48. Trollet, C., Y. Pereira, A. Burgain, E. Litzler, M. Mezrahi, J. Seguin, M. Manich, M. R. Popoff, D. Scherman, and P. Bigey. 2009. Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer. Infect. Immun. 77:2221-2229.
49. Tsuboi, T., S. Takeo, H. Iriko, L. Jin, M. Tsuchimochi, S. Matsuda, E. Han, H. Otsuki, O. Kaneko, J. Sattabongkot, R. Udomasangpetch, T. Sawasaki, M. Torii, and Y. Endo. 2008. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect. Immun. 76:1702-1708.
50. Voloshin, A. M., and J. R. Swartz. 2005. Efficient and scalable method for scaling up cell free protein synthesis in batch mode. Biotechnol. Bioeng. 91:516-521.
51. Volyanik, E. V., A. Dalley, I. A. McKay, I. Leigh, N. S. Williams, and S. A. Bustin. 1993. Synthesis of preparative amounts of biologically active interleukin- 6 using a continuous-flow cell-free translation system. Anal. Biochem. 214:289-294.
52. Webb, R. P., T. J. Smith, P. Wright, J. Brown, and L. A. Smith. 2009. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 27:4490-4497.
53. Webb, R. P., T. J. Smith, P. M. Wright, V. A. Montgomery, M. M. Meagher, and L. A. Smith. 2007. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 25:4273-4282.
54. Whelan, S. M., M. J. Elmore, N. J. Bodsworth, T. Atkinson, and N. P. Minton. 1992. The complete amino acid sequence of the Clostridium botulinum type E neurotoxin derived by sequence analysis of the encoding gene. Eur. J. Biochem. 204:657-667.
55. Whelan, S. M., M. J. Elmore, N. J. Bodsworth, J. K. Brehm, T. Atkinson, and P. Minton. 1992. Molecular cloning of the Clostridium botulinum structural gene gene encoding the type B neurotoxin and determination of its entire nucleotide sequence. Appl. Environ. Microbiol. 58:2345-2354.
56. Woodward, L. A., H. Arimitsu, R. Hirst, and K. Oguma. 2003. Expression of Hc subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Infect. Immun. 71:2941-2944.
57. Yu, Y. Z., N. Li, H. Q. Zhu, R. L. Wang, Y. Du, S. Wang, W. Y. Yu, and Z. W. Sun. 2009. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 27:2816-2822.
58. Zarebski, L. M., K. Vaughan, J. Sidney, B. Peters, H. Grey, K. D. Janda, A. Casadevall, and A. Sette. 2008. Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev. Vaccines 7:55-74.